ADMA Biologics, Inc. (NASDAQ:ADMA) Director Steve Elms Sells 137,931 Shares

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) Director Steve Elms sold 137,931 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $20.82, for a total transaction of $2,871,723.42. Following the transaction, the director now owns 282,079 shares of the company's stock, valued at approximately $5,872,884.78. The trade was a 32.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Steve Elms also recently made the following trade(s):

• On Thursday, June 12th, Steve Elms sold 92,941 shares of ADMA Biologics stock. The shares were sold at an average price of $21.69, for a total transaction of $2,015,890.29.
• On Monday, June 16th, Steve Elms sold 194,749 shares of ADMA Biologics stock. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76.

ADMA Biologics Trading Down 2.0%

Shares of ADMA Biologics stock opened at $20.40 on Tuesday. The firm has a market capitalization of $4.87 billion, a PE ratio of 72.86 and a beta of 0.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company's fifty day moving average price is $20.99 and its two-hundred day moving average price is $18.83. ADMA Biologics, Inc. has a 52-week low of $10.21 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company's quarterly revenue was up 40.2% compared to the same quarter last year. During the same period last year, the firm earned $0.08 EPS. On average, analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently bought and sold shares of ADMA. Nuveen LLC bought a new stake in shares of ADMA Biologics in the 1st quarter worth about $93,543,000. B Group Inc. bought a new stake in shares of ADMA Biologics in the 4th quarter worth about $39,231,000. Driehaus Capital Management LLC grew its holdings in shares of ADMA Biologics by 114.9% in the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company's stock worth $58,460,000 after purchasing an additional 1,575,363 shares during the last quarter. Invesco Ltd. grew its holdings in shares of ADMA Biologics by 13.9% in the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after purchasing an additional 1,570,649 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of ADMA Biologics in the 4th quarter worth about $19,076,000. Institutional investors own 75.68% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th. Raymond James upped their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $24.25.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.